Compare Crocs, Inc. (CROX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs TransMedics Group Inc — how do they compare? Crocs, Inc. trades at $131.17 (market cap $6.52B), while TransMedics Group Inc trades at $75 (market cap $2.58B). The key difference: Crocs, Inc. is far larger — about 2.5× TransMedics Group Inc's market cap, and Crocs, Inc. is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| CROX | TMDX | |
|---|---|---|
Market Cap | $6.52B | $2.58B |
Sector | Consumer Staples | Technology |
52-Week High | $132.78 | $150.42 |
52-Week Low | $73.39 | $61.99 |
Enterprise Value | $8.11B | $2.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $130.46, down 1.75% on the day, with strong technical momentum indicated by bullish moving averages and a potential breakout pattern forming. The company has consistently beaten earnings estimates in recent quarters, though 2025 showed a net loss of $81.20M. Strategic partnerships with LEGO and Disney are driving brand innovation, while international growth, particularly in Asia, provides expansion opportunities.
The stock presents a mixed outlook with bullish analyst sentiment (51% buy ratings) and a $131.29 consensus price target offering modest upside. Key risks include recent profitability challenges, high debt levels, and competitive pressures in the footwear sector. Revenue stability and brand strength support long-term potential, but margin recovery remains critical for sustained growth.
TransMedics (TMDX) trades at $75.74, up 6.33% today, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with support at $75 and resistance at $77. Recent strategic investments in European organ logistics through PAD Aviation position the company for international expansion, though margin pressure from these investments remains a concern. Analyst consensus remains strongly positive with a $108.71 price target.
The outlook remains favorable with 75% analyst buy ratings and significant upside potential from current levels. Key risks include execution challenges in European expansion, ongoing margin pressure from NOP investments, and competitive threats in the transplant logistics space. Revenue growth continues at 21% year-over-year, but investors should monitor margin trends and European rollout execution closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
